Bivalirudin Needs Closer Look in ACS, Study Suggests (CME/CE)

PARIS (MedPage Today) -- Whether clinicians chose bivalirudin (Angiomax) or heparin as monotherapy made no difference in outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing PCI, a registry study showed.

Source: MedPage Today State Required CME - May 22, 2013 Category: Consumer Health News Source Type: news